Lung Disease Clinical Trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 569 clinical trials
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.

durvalumab
lung carcinoma
chemoradiotherapy
  • 285 views
  • 19 Sep, 2021
  • 153 locations
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B and C), to estimate the antitumor activity of

gefitinib
epidermal growth factor receptor
EGFR
erlotinib
cancer chemotherapy
  • 5 views
  • 17 Sep, 2021
  • 92 locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

cancer treatment
epidermal growth factor receptor
EGFR
epidermal growth factor
stage iv non-small cell lung cancer
  • 30 views
  • 19 Sep, 2021
  • 342 locations
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared With Carboplatin-Pemetrexed in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

epidermal growth factor receptor
EGFR
epidermal growth factor
cancer chemotherapy
carboplatin
  • 1 views
  • 19 Sep, 2021
  • 285 locations
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

durvalumab
lung carcinoma
  • 35 views
  • 19 Sep, 2021
  • 197 locations
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

durvalumab
cancer chemotherapy
lung carcinoma
  • 106 views
  • 18 Sep, 2021
  • 249 locations
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na ve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC ) (MK-3475-01B/KEYMAKER-U01B)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-nave participants with advanced squamous or non-squamous NSCLC that is PD-L1 positive. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

mk-3475
pembrolizumab
lung carcinoma
  • 0 views
  • 05 Sep, 2021
  • 27 locations
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

intravenously in adults with advanced non-small cell lung cancer (NSCLC).

  • 17 views
  • 19 Sep, 2021
  • 18 locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and

pembrolizumab
pd-l1
progressive disease
biomarker analysis
docetaxel
  • 151 views
  • 19 Sep, 2021
  • 151 locations
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progressive free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

docetaxel
platinum-based chemotherapy
cancer
measurable disease
squamous non-small cell lung cancer
  • 23 views
  • 19 Sep, 2021
  • 218 locations